or Try an Advanced Search...

    Kidney Disease Stocks List

    Symbol Grade Name % Change
    CALT D Calliditas Therapeutics AB 4.06
    DMAC F DiaMedica Therapeutics Inc. -1.93
    AKBA F Akebia Therapeutics, Inc. -5.30
    AMPE F Ampio Pharmaceuticals, Inc. -33.95
    TVTX F Travere Therapeutics, Inc. 2.66
    RMTI F Rockwell Medical, Inc. -1.35
    ICU F SeaStar Medical Holding Corporation -5.53
    RNLX F Renalytix AI plc -2.51
    PIRS F Pieris Pharmaceuticals, Inc. -0.60
    FGEN F FibroGen, Inc 3.67
    View As Page of Charts
    Related Industries: Biotechnology Data Storage Diagnostics & Research Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Medical Instruments & Supplies
    Related Stock Lists: Biopharmaceutical Chronic Kidney Disease Renal Disease Anemia Biotechnology End Stage Renal Disease Life Sciences Medicine Stage Renal Disease Cancer Clinical Development Diabetic Nephropathy Dialysis Disease Dysfunction Gastrointestinal Heart Failure Hypoxia Inducible Factors Inflammation Inflammation Diseases

    Related ETFs - A few ETFs which own one or more of the above listed Kidney Disease stocks.

    Symbol Grade Name Weight
    PPH C Market Vectors Pharmaceutical ETF 5.59
    MEDX F Horizon Kinetics Medical ETF 4.77
    IBBQ C Invesco Nasdaq Biotechnology ETF 4.73
    FLUD A Franklin Liberty Ultra Short Bond ETF 4.07
    BIB D ProShares Ultra Nasdaq Biotechnology 3.46
    View all Kidney Disease ETFs...
    Compare ETFs
    Compare FLUD to BIB Compare MEDX to FLUD Compare MEDX to IBBQ

        Kidney Disease Stocks Recent News

        Date Stock Title
        Apr 29 TVTX Travere Therapeutics to Report First Quarter 2024 Financial Results
        Apr 29 CALT Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
        Apr 29 FGEN FibroGen to Report First Quarter 2024 Financial Results
        Apr 28 AKBA When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
        Apr 24 FGEN FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncolo...
        Apr 24 CALT Calliditas Therapeutics' 2023 Annual Report Published
        Apr 24 TVTX Travere, CSL win conditional nod for kidney disease therapy in EU
        Apr 24 TVTX Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
        Apr 24 CALT Calliditas Announces Positive NefIgArd Open Label Extension Results
        Apr 24 TVTX CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
        Related Industries: Biotechnology Data Storage Diagnostics & Research Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Medical Instruments & Supplies
        Related Stock Lists: Biopharmaceutical Chronic Kidney Disease Renal Disease Anemia Biotechnology End Stage Renal Disease Life Sciences Medicine Stage Renal Disease Cancer Clinical Development Diabetic Nephropathy Dialysis Disease Dysfunction Gastrointestinal Heart Failure Hypoxia Inducible Factors Inflammation Inflammation Diseases
        Kidney Disease

        Kidney disease is a condition in which the kidneys are damaged and unable to filter waste and toxins from the blood. This can lead to a buildup of waste and toxins in the body, which can cause a variety of symptoms, including fatigue, nausea, loss of appetite, and swelling in the hands and feet. In severe cases, kidney disease can lead to kidney failure, which requires dialysis or a kidney transplant.

        Browse All Tags